Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: The Liver Citrate Anticoagulation Threshold (L-CAT) observational study

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Slowinski, Torsten ^a   Morgera, Stanislao ^a   Joannidis, Michael ^b   Henneberg, Thomas ^a   Stocker, Reto ^c   Helset, Elin ^d   Andersson, Kirsti ^d   Wehner, Markus ^e   Kozik Jaromin, Justyna ^f   Brett, Sarah ^g   Hasslacher, Julia ^b   Stover, John F ^c   Peters, Harm ^a   Neumayer, Hans H ^a   Kindgen Milles, Detlef ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f Clinical Research   (Germany)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CITRIC ACID; ANTICOAGULANT AGENT;

ACIDOSIS; ADULT; AGED; ALKALOSIS; ANTICOAGULANT THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTINUOUS HEMODIALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS MACHINE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INTENSIVE CARE UNIT; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGIONAL CITRATE ANTICOAGULATION; UNSPECIFIED SIDE EFFECT; ACID BASE BALANCE; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; HEMODIALYSIS; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ACID-BASE EQUILIBRIUM; ACIDOSIS; AGED; ALKALOSIS; ANTICOAGULANTS; CITRIC ACID; FEMALE; HUMANS; HYPOCALCEMIA; INTENSIVE CARE UNITS; LIVER FAILURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84942509895     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-1066-7     Document Type: Article

References (31)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1-138.
2. Betjes MG, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol. 2007;20:602-8.
3. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant. 2011;26:232-9.
4. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67:2361-7.
5. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260-5.
6. Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009;37:2018-24.
7. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545-52.
8. Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care. 2007;11:218.
9. Nicholls DG, Garland PB. The control of isocitrate oxidation by rat liver mitochondria. Biochem J. 1969;114:215-25.
10. Kindgen-Milles D, Amman J, Kleinekofort W, Morgera S. Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation. Int J Artif Organs. 2008;31:363-6.
11. Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29:748-52.
12. Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31:2450-5.
13. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol. 2010;53:362-71.
14. Agarwal B, Shaw S, Hari MS, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? J Hepatol. 2009;51:504-9.
15. Schultheiss C, Saugel B, Phillip V, Thies P, Noe S, Mayr U, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;16:R162.
16. Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, et al. Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med. 2011;39:273-9.
17. Morimatsu H, Uchino S, Bellomo R, Ronco C. Continuous renal replacement therapy: does technique influence electrolyte and bicarbonate control? Int J Artif Organs. 2003;26:289-96.
18. Zivin JR, Gooley T, Zager RA, Ryan MJ. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am J Kidney Dis. 2001;37:689-98.
19. Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med. 1988;84:209-14.
20. Kindgen-Milles D, Kram R, Kleinekofort W, Morgera S. Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation. ASAIO J. 2008;54:442-4.
21. König T, Nicholls DG, Garland PB. The inhibition of pyruvate and l s(+)-isocitrate oxidation by succinate oxidation in rat liver mitochondria. Biochem J. 1969;114:589-96.
22. Gong D, Ji D, Xu B, Xie H, Liu Y, Li L. Regional citrate anticoagulation in critically ill patients during continuous blood purification. Chin Med J (Engl). 2003;116:360-3.
23. Chappell JB. The oxidation of citrate, isocitrate and cis-aconitate by isolated mitochondria. Biochem J. 1964;90:225-37.
24. Khadzhynov D, Schelter C, Lieker I, Mika A, Staeck O, Neumayer HH, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care. 2014;29:265-71.
25. Meyers LL, Beierschmitt WP, Khairallah EA, Cohen SD. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol Appl Pharmacol. 1988;93:378-87.
26. Ramsay RR, Rashed MS, Nelson SD. In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria. Arch Biochem Biophys. 1989;273:449-57.
27. James MF, Roche AM. Dose-response relationship between plasma ionized calcium concentration and thrombelastography. J Cardiothorac Vasc Anesth. 2004;18:581-6.
28. Calatzis A, Toepfer M, Schramm W, Spannagl M, Schiffl H. Citrate anticoagulation for extracorporeal circuits: effects on whole blood coagulation activation and clot formation. Nephron. 2001;89:233-6.
29. Moseley RH. Sepsis and cholestasis. Clin Liver Dis. 2004;8:83-94.
30. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439-45.
31. Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, Böhler J. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant. 2009;24:2244-51.